Gallery
- PM Modi visit USAOnly the mirror in my washroom and phone gallery see the crazy me : Sara KhanKarnataka rain fury: Photos of flooded streets, uprooted treesCannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfitRanbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A KissOscars 2022: Every Academy Award WinnerShane Warne (1969-2022): Australian cricket legend's life in picturesPhotos: What Russia's invasion of Ukraine looks like on the groundLata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)
The 18-year-old, Chirag Chikkara clinched a gold medal in the men’s freestyle 57kg categ
- FIFA president Infantino confirms at least 9 African teams for the 2026 World Cup
- Hockey, cricket, wrestling, badminton, squash axed from 2026 CWG in Glasgow
- FIFA : Over 100 female footballers urge FIFA to reconsider partnership with Saudi oil giant
- Ecuador ready to make history against Uruguay: Beccacece
- Divanshi wins second gold as India sweep women's 25m standard pistol at Lima Junior Worlds
Ivermectin, HCQ not part of 'clinical management' for adult Covid patients Last Updated : 24 Sep 2021 01:23:58 PM IST Two commonly used drugs Ivermectin and Hydroxychloroquine (HCQ) have been dropped from the revised clinical guidance for management of adult Covid 19 patients.
The All India Institute of Medical Sciences (AIIMS) and the Indian Council of Medical Research (ICMR) Covid-19 national task force has made the recommendation to drop the use of these two drugs in its revised guidelines.The clinical guidance version dated May 19, 2021, prepared jointly by the AIIMS and ICMR -- national task force for Covid-19 and the Joint Monitoring Group was reviewed on August 20, in the context of emerging evidence of Ivermactine and hydroxychloroquine. After review, the medicines were removed from the guidance document.The reasons behind dropping Hydroxychloroquine also included no mortality benefit, increases the risk of address drug effect (ADE) when co-administered with Azithromycin."HCQ may be considered for removal from guideline, with recommendation to use with caution only in clinical trial setting (since there is some genuine uncertainty regarding the possible benefit for severe cases and in low dose). Many studies showing increased mortality risk (10/13) and low mortality benefit of HCQ(2/13). Considering evidence for increased ADE(6/13) , especially with azithromycin and only one study showed no increase in ADE(1/13)," said the revised guidelines for Covid management.In the case of Ivermectin, it said, " Ivermectin may be considered for removal from guideline, with recommendation to use only in clinical trial setting until warranted by more conclusive large-scale randomized controlled trials due to the reason that many studies show mortality benefit, and no evidence for increased mortality. High risk of bias in many studies (especially with the ones showing benefit), level of certainty for mortality benefit is low."IANS New Delhi For Latest Updates Please-
Join us on
Follow us on
172.31.16.186